Showcases Stock ranks Forex

Deciphera Pharmaceuticals Inc (DCPH)
34.6  0.56 (1.65%) 10-22 16:00
Open: 33.49 Pre. Close: 34.04
High: 34.65 Low: 32.74
Volume: 235,369 Market Cap: 2,008M
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 34.675 - 34.84 34.84 - 34.994
Low: 32.331 - 32.515 32.515 - 32.688
Close: 34.288 - 34.587 34.587 - 34.867
Stock Technical Analysis
Target: Six months: 41.90
One year: 48.93
Support: Support1: 32.43
Support2: 30.30
Resistance: Resistance1: 35.87
Resistance2: 41.90
Pivot: 33.58
Moving Averages: MA(5): 34.14
MA(20): 33.64
MA(100): 32.95
MA(250): 42.47
MACD: MACD(12,26): 0.58
Signal(12,26,9): 0.56
%K %D: %K(14,3): 71.64
%D(3): 68.76
RSI: RSI(14): 58.08
52-Week: High: 68.4
Low: 26.2
Change(%): -44.8
Average Vol(K): 3-Month: 37526
10-Days: 30227
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

DCPH has closed below upper band by 28.0%. Bollinger Bands are 1.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Fri, 22 Oct 2021
3 Biotech Stocks With Huge Catalysts Incoming - Nasdaq

Thu, 21 Oct 2021
Zacks: Brokerages Anticipate Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Will Announce Quarterly Sales of $23.73 Million - MarketBeat

Wed, 20 Oct 2021
Deciphera (DCPH) gains 0.71% in Light Trading on October 20 -

Fri, 15 Oct 2021
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe - Nasdaq

Tue, 12 Oct 2021
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor - Business Wire

Sun, 10 Oct 2021
Have Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Insiders Been Selling Their Stock? - Nasdaq

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 57.96
Shares Float (M) 36.66
% Held by Insiders 29.42
% Held by Institutions 76.82
Shares Short (K) 3130
Shares Short Prior Month (K) 3270
Stock Financials
EPS -4.490
Book Value (p.s.) 8.690
Profit Margin
Operating Margin -383.18
Return on Assets (ttm) -24.2
Return on Equity (ttm) -43.4
Qtrly Rev. Growth 40474.2
Gross Profit (p.s.) -2.711
Sales Per Share 1.159
EBITDA (p.s.) -4.397
Qtrly Earnings Growth
Operating Cash Flow (M) -227.00
Levered Free Cash Flow (M) -137.13
Stock Valuation
PE Ratio -7.71
PEG Ratio
Price to Book value 3.98
Price to Sales 29.85
Price to Cash Flow -8.83
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator